BR112023001152A2 - Uso de proteínas ligadoras de heparina (hbp) em alerta precoce de risco prognóstico para pacientes com doença de coronavírus (covid-19) - Google Patents

Uso de proteínas ligadoras de heparina (hbp) em alerta precoce de risco prognóstico para pacientes com doença de coronavírus (covid-19)

Info

Publication number
BR112023001152A2
BR112023001152A2 BR112023001152A BR112023001152A BR112023001152A2 BR 112023001152 A2 BR112023001152 A2 BR 112023001152A2 BR 112023001152 A BR112023001152 A BR 112023001152A BR 112023001152 A BR112023001152 A BR 112023001152A BR 112023001152 A2 BR112023001152 A2 BR 112023001152A2
Authority
BR
Brazil
Prior art keywords
covid
hbp
patients suffering
heparin
patients
Prior art date
Application number
BR112023001152A
Other languages
English (en)
Inventor
Sun Baoqing
Zhong Nanshan
Zhou Xuyi
Xue Mingshan
Hong Longbin
Dong Ming
Original Assignee
Joinstar Biomedical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joinstar Biomedical Tech Co Ltd filed Critical Joinstar Biomedical Tech Co Ltd
Publication of BR112023001152A2 publication Critical patent/BR112023001152A2/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/80—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0635—Risk analysis of enterprise or organisation activities
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/60—Analysis of geometric attributes
    • G06T7/62—Analysis of geometric attributes of area, perimeter, diameter or volume
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30048—Heart; Cardiac
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30061—Lung

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Human Resources & Organizations (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Theoretical Computer Science (AREA)
  • Strategic Management (AREA)
  • Economics (AREA)
  • Primary Health Care (AREA)
  • Educational Administration (AREA)
  • Development Economics (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Quality & Reliability (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tourism & Hospitality (AREA)
  • Operations Research (AREA)
  • General Business, Economics & Management (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Marketing (AREA)
  • Game Theory and Decision Science (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)

Abstract

USO DE PROTEÍNAS LIGADORAS DE HEPARINA (HBP) EM ALERTA PRECOCE DE RISCO PROGNÓSTICO PARA PACIENTES COM DOENÇA DE CORONAVÍRUS (COVID-19). São fornecidos um método para previsão de risco de deterioração de uma condição patogênica em pacientes sofrendo de uma doença de coronavírus (COVID-19), especialmente aqueles pacientes sofrendo de COVID-19 grave e um kit do mesmo. O método do presente pedido pode prever de forma eficaz a deterioração da condição patogênica de pacientes sofrendo de COVID-19, permitindo assim uma intervenção clínica precoce, melhorando o prognóstico dos pacientes sofrendo de COVID-19. O presente pedido identificou pela primeira vez que o nível de uma proteína ligadora de heparina (HBP) pode ser usado como um indicador significativo da previsão precoce de recidiva em pacientes sofrendo de COVID-19, o tempo de expressão de um indicador de HBP é em torno de 5 dias mais cedo do que uma série de outros indicadores clínicos, e, então, o indicador de HBP particularmente tem um valor clínico.
BR112023001152A 2020-07-30 2020-09-29 Uso de proteínas ligadoras de heparina (hbp) em alerta precoce de risco prognóstico para pacientes com doença de coronavírus (covid-19) BR112023001152A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010750016.XA CN111951963B (zh) 2020-07-30 2020-07-30 Hbp在covid-19患者的预后风险预警中的应用
PCT/CN2020/118688 WO2022021597A1 (zh) 2020-07-30 2020-09-29 Hbp在covid-19患者的预后风险预警中的应用

Publications (1)

Publication Number Publication Date
BR112023001152A2 true BR112023001152A2 (pt) 2023-02-14

Family

ID=73338002

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001152A BR112023001152A2 (pt) 2020-07-30 2020-09-29 Uso de proteínas ligadoras de heparina (hbp) em alerta precoce de risco prognóstico para pacientes com doença de coronavírus (covid-19)

Country Status (6)

Country Link
US (1) US20230236195A1 (pt)
EP (1) EP4191610A1 (pt)
JP (1) JP2023534744A (pt)
CN (1) CN111951963B (pt)
BR (1) BR112023001152A2 (pt)
WO (1) WO2022021597A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
CN108051439A (zh) * 2017-12-25 2018-05-18 苏州康和顺医疗技术有限公司 一种单试剂肝素结合蛋白检测试剂盒及其制备方法
CN108152512A (zh) * 2017-12-25 2018-06-12 苏州康和顺医疗技术有限公司 肝素结合蛋白检测试剂盒及其制备方法
CN110806487A (zh) * 2019-12-02 2020-02-18 深圳上泰生物工程有限公司 一种用于人肝素结合蛋白检测的试剂盒及其制备方法
CN111184805B (zh) * 2020-03-06 2021-07-23 江西曹洞慈善基金会 一种中药组合物及其应用
ES2970340T3 (es) * 2020-03-24 2024-05-28 Drk Blutspendedienst Baden Wuerttemberg Hessen Gemeinnuetzige Gmbh Detección de SARS-COV-2 en una pluralidad de muestras biológicas
CN111358905A (zh) * 2020-04-10 2020-07-03 华中科技大学同济医学院附属协和医院 一种治疗肺炎的中药合剂及其制备方法

Also Published As

Publication number Publication date
CN111951963A (zh) 2020-11-17
US20230236195A1 (en) 2023-07-27
JP2023534744A (ja) 2023-08-10
EP4191610A1 (en) 2023-06-07
WO2022021597A1 (zh) 2022-02-03
CN111951963B (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
Paffrath et al. How to define severely injured patients?—An Injury Severity Score (ISS) based approach alone is not sufficient
Schmidt et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study
Mahmoodi et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin
Kornblith et al. Obesity and clotting: body mass index independently contributes to hypercoagulability after injury
Sekulic et al. Scoring systems in assessing survival of critically ill ICU patients
Güzel et al. The value of the serum I-FABP level for diagnosing acute mesenteric ischemia
Domanovits et al. Acute phase reactants in patients with abdominal aortic aneurysm
Javed et al. Clinical predictors of early death from sepsis
McCormack et al. Fournier’s gangrene: A retrospective analysis of 26 cases in a Canadian hospital and literature review
Bennett et al. Hyperlactemia predicts surgical mortality in patients presenting with acute stanford type-A aortic dissection
Iba et al. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation
Freynhofer et al. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation
Mommersteeg et al. Type D personality and patient-perceived health in nonsignificant coronary artery disease: the TWeesteden mIld STenosis (TWIST) study
Kim et al. FMD and SCAD: sex-biased arterial diseases with clinical and genetic pleiotropy
Zielińska-Borkowska et al. Monitoring of procalcitonin but not interleukin-6 is useful for the early prediction of anastomotic leakage after colorectal surgery
Wenchao et al. Association of matrix metalloproteinase-9 gene− 1562C/T polymorphism with essential hypertension: A systematic review and meta-analysis article
Davies et al. Idiopathic degenerative thoracic aneurysms are associated with increased aortic medial amyloid
Nobel et al. Surveillance implications of recurrence patterns in early node-negative esophageal adenocarcinoma
Kopytek et al. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients
Skouras et al. Early organ dysfunction affects long-term survival in acute pancreatitis patients
Afshar et al. Injury Characteristics and von Willebrand factor for the prediction of acute respiratory distress syndrome in patients with burn injury: development and internal validation
Hung et al. Impact of pre-, intra-and post-operative parameters on in-hospital mortality in patients undergoing emergency coronary artery bypass grafting: a scarce single-center experience in resource-scare setting
BR112023001152A2 (pt) Uso de proteínas ligadoras de heparina (hbp) em alerta precoce de risco prognóstico para pacientes com doença de coronavírus (covid-19)
Memon et al. Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism
Lecumberri et al. Prognostic value of inflammatory biomarkers in 5-year survival after endovascular repair of abdominal aortic aneurysms in a predominantly male cohort: implications for practice